



2 December 2020

## **Creso receives new purchase orders for leading anibidiol® products underpinning growing demand in EU region**

### **Highlights**

- **Three purchase orders (POs) secured for anibidiol® products totalling A\$414,000 (CHF277,000) - bringing total POs generated by animal health segment to ~A\$975,000 (CHF634,000) in 2020.**
- **Illustrate product demand and robust sales pipeline despite regulatory challenges**
- **Product portfolio expansion initiatives underway to grow animal health sector footprint**

**Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company')** is pleased to advise it has received three new purchase orders (POs) for its anibidiol® line of animal health products totalling CHF277,000 (A\$414,000).

The new orders take total purchase orders generated through Creso Pharma's animal health segment to ~A\$975,000 (CHF634,000) for 2020, outlining the strong demand for the Company's industry leading products. Revenues in the first half of 2020 were CHF 354,404 (A\$ 529,687).

Current orders are expected to be shipped to commercial partners in Europe in the coming weeks, partners will then market the products to consumers more broadly.

These orders are a significant achievement for Creso Pharma and highlight the Company's ability to navigate stringent regulatory requirements for marketing hemp products across Europe, as well as management's ability to progress growth initiatives in difficult market conditions.

Demand for the products remains high and these additional POs serve as further confirmation of the success of the anibidiol® product line in the rapidly growing European animal health market.

The product uptake since 2017 continues totalling 4 million anibidiol® doses in purchase orders. Creso is continuing to explore plans to expand its animal health portfolio with additional innovative products such as various hemp-flour and hemp seed oil products. With growing demand for its existing products, the Company is also progressing strategies to increase its footprint in the sector.

In light of the recent regulatory changes, the Company sees the EU and global markets expanding rapidly and Creso is extremely well positioned to benefit from this.

### **Management Commentary**

**Creso Pharma's Commercial Director Jorge Wernli said:** "These purchase orders are a major achievement for the Company during this challenging regulatory situation and COVID-19 time. They further highlight the demand we are witnessing for our innovative products across Europe and vindicates the Company's strategy of investing in its animal health business."

"We expect the animal health segment to continue to grow, with additional purchase orders expected in the coming months. Management are also exploring a number of ways to further unlock the market, and we believe we are well-placed to progress a number of initiatives to grow our footprint in this space."



**-Ends-**

### **Authority and Contact Details**

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

### **Investor Enquiries**

Ben Jarvis – Six Degrees Media  
P: +61 2 9230 0661

EverBlu Capital  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

### **About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.